152 related articles for article (PubMed ID: 38319800)
1. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Clarke NW; Armstrong AJ; Thiery-Vuillemin A; Oya M; Shore N; Loredo E; Procopio G; de Menezes J; Girotto G; Arslan C; Mehra N; Parnis F; Brown E; Schlürmann F; Joung JY; Sugimoto M; Virizuela JA; Emmenegger U; Navratil J; Buchschacher GL; Poehlein C; Harrington EA; Desai C; Kang J; Saad F
NEJM Evid; 2022 Sep; 1(9):EVIDoa2200043. PubMed ID: 38319800
[TBL] [Abstract][Full Text] [Related]
2. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
3. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Saad F; Clarke NW; Oya M; Shore N; Procopio G; Guedes JD; Arslan C; Mehra N; Parnis F; Brown E; Schlürmann F; Joung JY; Sugimoto M; Sartor O; Liu YZ; Poehlein C; Barker L; Del Rosario PM; Armstrong AJ
Lancet Oncol; 2023 Oct; 24(10):1094-1108. PubMed ID: 37714168
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
5. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M
N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With
Fallah J; Xu J; Weinstock C; Brave MH; Bloomquist E; Fiero MH; Schaefer T; Pathak A; Abukhdeir A; Bhatnagar V; Chiu HJ; Ricks T; John C; Hamed S; Lee C; Pierce WF; Kalavar S; Philip R; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman D
J Clin Oncol; 2024 Feb; 42(5):605-613. PubMed ID: 38127780
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone-Olaparib Combo Aids Men with mCRPC.
Cancer Discov; 2018 Aug; 8(8):OF4. PubMed ID: 29954730
[TBL] [Abstract][Full Text] [Related]
8. Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer.
Giesen A; Devlies W; Claessens F; Joniau S
Eur Urol; 2024 Apr; 85(4):396. PubMed ID: 38016839
[No Abstract] [Full Text] [Related]
9. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Thiery-Vuillemin A; de Bono J; Hussain M; Roubaud G; Procopio G; Shore N; Fizazi K; Dos Anjos G; Gravis G; Joung JY; Matsubara N; Castellano D; Degboe A; Gresty C; Kang J; Allen A; Poehlein C; Saad F
Lancet Oncol; 2022 Mar; 23(3):393-405. PubMed ID: 35157830
[TBL] [Abstract][Full Text] [Related]
10. Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108.
Liu M; Chen P; Li T
Eur Urol; 2024 Jun; 85(6):e176-e177. PubMed ID: 38135561
[No Abstract] [Full Text] [Related]
11. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Hussain M; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Roubaud G; Özgüroğlu M; Kang J; Burgents J; Gresty C; Corcoran C; Adelman CA; de Bono J;
N Engl J Med; 2020 Dec; 383(24):2345-2357. PubMed ID: 32955174
[TBL] [Abstract][Full Text] [Related]
12. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
[TBL] [Abstract][Full Text] [Related]
13. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Sweeney C; Bracarda S; Sternberg CN; Chi KN; Olmos D; Sandhu S; Massard C; Matsubara N; Alekseev B; Parnis F; Atduev V; Buchschacher GL; Gafanov R; Corrales L; Borre M; Stroyakovskiy D; Alves GV; Bournakis E; Puente J; Harle-Yge ML; Gallo J; Chen G; Hanover J; Wongchenko MJ; Garcia J; de Bono JS
Lancet; 2021 Jul; 398(10295):131-142. PubMed ID: 34246347
[TBL] [Abstract][Full Text] [Related]
14. Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108.
Saad F; Del Rosario P; Clarke NW
Eur Urol; 2024 Jun; 85(6):e178-e179. PubMed ID: 38042647
[No Abstract] [Full Text] [Related]
15. Re: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial.
Taneja SS
J Urol; 2019 Apr; 201(4):667. PubMed ID: 30653001
[No Abstract] [Full Text] [Related]
16. Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer.
Martini A; Fallara G; Ploussard G; Malavaud B
Lancet Oncol; 2023 Oct; 24(10):1056-1057. PubMed ID: 37797626
[No Abstract] [Full Text] [Related]
17. Should We "PROpel" Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?
VanderWeele DJ; Hussain M
NEJM Evid; 2022 Sep; 1(9):EVIDe2200154. PubMed ID: 38319811
[TBL] [Abstract][Full Text] [Related]
18. Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.
Matsubara N; Nishimura K; Kawakami S; Joung JY; Uemura H; Goto T; Kwon TG; Sugimoto M; Kato M; Wang SS; Pang ST; Chen CH; Fujita T; Nii M; Shen L; Dujka M; Hussain M; de Bono J
Jpn J Clin Oncol; 2022 May; 52(5):441-448. PubMed ID: 35229141
[TBL] [Abstract][Full Text] [Related]
19. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
